Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective randomized, double-blind, placebo-controlled study in participants with
disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).